Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cixutumumab + Everolimus + Octreotide acetate|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cixutumumab||IMC-A12||IGF1R Antibody 8||Cixutumumab (IMC-A12) is an antibody against membrane-bound IGF-1R that prevents IGF-1 binding, inhibiting PI3K/AKT pathway activation and potentially leading to decreased tumor cell proliferation and increased tumor cell death (PMID: 29520435, PMID: 29909907).|
|Everolimus||Afinitor||RAD001|Zortress||mTORC1 Inhibitor 8||Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, in adult and pediatric patients aged 1 year and older with tuberous sclerosis complex who have subependymal giant cell astrocytoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov).|
|Octreotide acetate||Sandostatin Lar Depot||SMS 201-995||Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, inhibiting growth hormone, glucagon, and insulin, decreasing LH response to gonadotropin-releasing hormone, decreasing splanchnic blood flow, and inhibiting the release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||neuroendocrine tumor||not applicable||Cixutumumab + Everolimus + Octreotide acetate||Phase I||Actionable||In a Phase I trial, patients with neuroendocrine tumors treated with the combination of Cixutumumab, Sandostatin Lar Depot (octreotide acetate), and Afinitor (everolimus) demonstrated some efficacy, however, the drug combination did result in multiple non-dose limiting toxicities preventing long term tolerance (PMID: 25900182).||25900182|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|